BARDA Awards DxTerity Diagnostics $150M Contract for Radiation Exposure Test

Oct 05, 2016

NEW YORK (GenomeWeb) — The US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $150 million to DxTerity Diagnostics to develop and deliver its REDI-Dx biodosimetry test for radiation exposure, the firm announced today.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

BARDA Awards DxTerity Diagnostics $150M Contract for Radiation Exposure Test

To read the full story....

Breaking News

Centogene Q4 Revenues Grow Almost Fivefold, Driven by COVID-19 Testing

Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B

Snibe Diagnostic Obtains CE Mark for HIV Chemiluminescence Immunoassay

Antelope Dx Collaborates With In The Pocket, Extra Horizon to Develop Self-Tests

FDA Grants EUAs for SARS-CoV-2 Tests From Clinical Enterprise, Qorvo Biotechnologies

GenScript Biotech, IES Diagnostics Partner to Distribute SARS-CoV-2 Antibody Kit

Featured White Papers

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

Labs Craft SARS-CoV-2 Variant Genotyping Assays for Screening, Surveillance

FDA Grants EUAs for SARS-CoV-2 Tests From Clinical Enterprise, Qorvo Biotechnologies

Centogene Q4 Revenues Grow Almost Fivefold, Driven by COVID-19 Testing

Sponsorships